Drug intelligence / Profile preview

OLANI

Development stage: Unknown
Lead developer: GoMedical
Modality: Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Subcutaneous Implant

Overview

OLANI is a biodegradable, long-acting **naltrexone implant** developed to provide extended treatment for opioid use disorder. Implanted subcutaneously in the abdomen via a minor surgical procedure, it gradually dissolves and releases naltrexone over a 6-month period, aiming to improve medication adherence and reduce relapse rates in opioid-dependent patients. This product is a novel formulation of naltrexone distinguished from existing monthly injectable products by its extended duration of pharmacological action and biodegradable matrix.[1]

Brand names: OLANI
Other names: O’Neil Long Acting Naltrexone Implant

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on OLANI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OLANI.

Explore the full profile